Locally Advanced Head and Neck Squamous Cell Carcinoma
Conditions
Interventions
Drug: Dostarlimab
Dostarlimab will be administered intravenously.
Sponsors
Ishibashi Hideyasu
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Participants are eligible to be included in the study only if all of the following criteria apply, - Has newly diagnosed unresected LA histologically confirmed HNSCC of the oral cavity, oropharynx, hypopharynx or larynx and completed cisplatin plus radiotherapy (termed 'CRT' in this protocol) with curative intent and has no evidence of distant metastatic disease. - Has provided acceptable core or excisional tissue demonstrating, -PD-L1 positive tumor status -If the primary tumor site is oropharyngeal carcinoma, the participant must have p16 IHC testing. - Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - Has adequate organ function.
Exclusion criteria
Exclusion criteria: Participants are excluded from the study if any of the following criteria apply, - Has received prior radiation therapy, systemic therapy, targeted therapy, or radical surgery for management of head and neck cancer not considered part of CRT. - Has cancer outside of the oropharynx, larynx, hypopharynx or oral cavity, such as nasopharyngeal, sinus, other para-nasal, or other unknown primary head and neck cancer. - Has undergone any major surgical procedure or experienced significant traumatic injury within 28 days prior to enrollment. - Has any history of interstitial lung disease or pneumonitis (past or current). - Has cirrhosis or current unstable liver biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, or persistent jaundice. - Has a history or current evidence of any medical condition, therapy, or laboratory abnormality that might confound the study results, interfere with their participation for the full duration of the study intervention, or indicate it is not in the best interest of the participant to participate, in the opinion of the investigator. - Is receiving any other anticancer or experimental therapy. No other experimental therapies (including but not limited to chemotherapy, radiation, hormonal treatment, antibody therapy, immunotherapy, gene therapy, vaccine therapy, or other experimental drugs) of any kind are permitted while the participant is receiving study intervention. - Previous treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or an agent directed to another stimulatory or coinhibitory T-cell receptor (e.g., Cytotoxic T-lymphocyte associated protein 4 (CTLA4), OX-40, CD137). - Is pregnant, breastfeeding, or expecting to conceive children within the projected duration of the study, starting with the Screening Visit through 120 days after the last dose of study intervention. - Has a history of severe allergic and/or anaphylactic reactions to chimeric, human or humanized antibodies, fusion proteins, or known allergies to dostarlimab or its excipients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Event-free survival (EFS) assessed by blinded independent central review (BICR) | — |
Secondary
| Measure | Time frame |
|---|---|
| - Overall survival (OS) - EFS assessed by investigators - Ssafety and tolerability - Pharmacokinetics of dostarlimab - Immunogenicity of dostarlimab | — |
Countries
Argentina, Australia, Belgium, Brazil, Canada, China, Czechia, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Korea, Republic of, Mexico, New Zealand, Norway, Poland, Portugal, Romania, Spain, Sweden, Taiwan, Turkiye, United Kingdom, United States
Contacts
Public ContactHideyasu Ishibashi
GlaxoSmithKline K.K.
Outcome results
None listed